Skip to content

To compare the efficacy and safety of Herbavate vs. the conventional therapy in the management of Palmoplantar Keratoderma.

An open label, prospective, randomized, comparative, multi centre, clinical study comparing the efficacy and safety of herbavate vs. conventional therapy in the management of Palmoplantar Keratoderma.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2009/091/000756
Enrollment
150
Registered
2009-10-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Palmoplantar Keratoderma

Interventions

Intervention1: Herbavate: To be applied on affected area 3 times a day for 4 weeks Control Intervention1: Topical Salicylic Acid (6% w/w): To be applied on affected area 3 times a day for 4 weeks

Sponsors

Troikaa Pharmaceuticals Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 18 years of age or older. Clinical diagnosis of isolated (simple) palmoplantar keratoderma involving greter than or equal to 50 percent of the surface of involved acral areas. Be generally healthy as determined by brief medical history. Be capable of understanding and signing the consent form.

Exclusion criteria

Exclusion criteria: Have keratoderma associated with malignancy infection or systemic disease. Drug or toxin induced keratoderma when patient cannot avoid exposure to drug or toxin. PPK involving grater than 50 percent of the surface of involved acral areas. Have had therapy with potent topical corticosteroids within one month prior to enrollment; Have used systemic treatment with oral retinoids, corticosteroids, or with PUVA within the 8 week period prior to the beginning of the study; Are pregnant or lactating, or women not using highly effective contraception; Current participation in any other interventional clinical trial; Patients who have received treatment with any nonmarketed drug substance (i.e. an agent which has not yet been made available for clinical use) within 4 weeks prior to randomisation; Patient known or, in the opinion of the investigator, is unlikely to comply with the Clinical Study Protocol (e.g. alcoholism, drug dependency, or psychotic state).

Design outcomes

Primary

MeasureTime frame
Percentage reduction in area of involvementTimepoint: At the end of 2 and 4 weeks of treatment.

Secondary

MeasureTime frame
Global assessment by patients.( PaGA)Timepoint: End of Study (After 4 weeks);Improvement in symptomsTimepoint: At the end of 2 and 4 weeks of treatment.

Countries

India

Contacts

Public ContactDr Vijaya Jaiswal

Troikaa Pharmaceuticals Limited

vijayajaiswal@troikaapharma.com079-26856242

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026